Ken Fisher
CDTX

Ken Fisher’s Cidara Therapeutics CDTX Stock Holding History

Ken Fisher’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-825
Closed -$12K – 1143
2022
Q4 		$12K Hold
825
– – ﹤0.01% 1016
2022
Q3 		$10K Sell
825
-115
-12% -$1.59K ﹤0.01% 925
2022
Q2 		$9K Buy
+940
New +$11.6K ﹤0.01% 914

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ken Fisher's CDTX Position: Q1 2023 in Review

Ken Fisher sold out of Cidara Therapeutics (CDTX) in Q1 2023, closing a stake of 825 shares — an estimated $12K sold.

Ken Fisher first reported a position in CDTX in Q2 2022 and held it in 3 quarters. The position peaked at $12K in Q4 2022. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2023.

  • Ken Fisher reported no remaining Cidara Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ken Fisher sold 825 Cidara Therapeutics shares in Q1 2023, an estimated $12K.
  • Ken Fisher first reported a position in Cidara Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ken Fisher's Cidara Therapeutics position peaked at $12K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2023.

Based on Fisher Asset Management's 13F filing for Q1 2023, filed 1 May 2023.